News
LNSR
6.75
+2.74%
0.18
Lensar Price Target Announced at $11.00/Share by LUCID CAPITAL MARKETS
Dow Jones · 6d ago
LUCID CAPITAL MARKETS Initiates Coverage On LENSAR with Buy Rating, Announces Price Target of $11
Benzinga · 6d ago
Lensar initiated with a Buy at Lucid Capital
TipRanks · 6d ago
Weekly Report: what happened at LNSR last week (0921-0925)?
Weekly Report · 6d ago
Weekly Report: what happened at LNSR last week (0914-0918)?
Weekly Report · 09/21 10:04
Weekly Report: what happened at LNSR last week (0907-0911)?
Weekly Report · 09/14 10:08
Weekly Report: what happened at LNSR last week (0831-0904)?
Weekly Report · 09/07 10:03
Weekly Report: what happened at LNSR last week (0824-0828)?
Weekly Report · 08/31 10:09
Lake Street Keeps Their Buy Rating on LENSAR (LNSR)
TipRanks · 08/25 13:35
Weekly Report: what happened at LNSR last week (0817-0821)?
Weekly Report · 08/24 10:09
LENSAR (LNSR) Receives a Buy from BTIG
TipRanks · 08/20 11:35
Lensar Is Maintained at Buy by BTIG
Dow Jones · 08/20 10:26
Lensar Price Target Raised to $10.00/Share From $9.00 by BTIG
Dow Jones · 08/20 10:26
Weekly Report: what happened at LNSR last week (0810-0814)?
Weekly Report · 08/17 10:10
Lensar price target raised to $13 from $10 at Lake Street
TipRanks · 08/17 07:17
Lensar management to meet virtually with Lake Street
TipRanks · 08/16 13:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS)
TipRanks · 08/13 17:20
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 08/13 17:05
Lensar Is Maintained at Buy by BTIG
Dow Jones · 08/13 16:14
Lensar Price Target Raised to $9.00/Share From $7.00 by BTIG
Dow Jones · 08/13 16:14
More
Webull provides a variety of real-time LNSR stock news. You can receive the latest news about Lensar Inc through multiple platforms. This information may help you make smarter investment decisions.
About LNSR
LENSAR, Inc. is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. The Company's product portfolio includes the LENSAR Laser System and the ALLY Robotic Cataract Laser System and their associated consumable components. It has developed its ALLY System as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating artificial intelligence into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing its advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite. ALLY allows the surgeon to switch between cataract laser and the surgeon’s existing phacoemulsification device without moving patients from room-to-room. ALLY includes its proprietary Streamline software technology.